Published in Clin Exp Metastasis on January 01, 2004
Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol (2009) 1.34
Grb2 signaling in cell motility and cancer. Expert Opin Ther Targets (2008) 1.32
SUMOylation of Grb2 enhances the ERK activity by increasing its binding with Sos1. Mol Cancer (2014) 0.92
Distinct phosphotyrosine-dependent functions of the ShcA adaptor protein are required for transforming growth factor β (TGFβ)-induced breast cancer cell migration, invasion, and metastasis. J Biol Chem (2012) 0.82
Keratinocyte growth factor stimulates growth of MIA PaCa-2 cells through extracellular signal-regulated kinase phosphorylation. Oncol Lett (2011) 0.76
The heparan sulfate sulfotransferase 3-OST3A (HS3ST3A) is a novel tumor regulator and a prognostic marker in breast cancer. Oncogene (2016) 0.75
Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature (1994) 10.34
The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell (1992) 8.20
The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature (1993) 7.11
Ras1 and a putative guanine nucleotide exchange factor perform crucial steps in signaling by the sevenless protein tyrosine kinase. Cell (1991) 5.87
C. elegans cell-signalling gene sem-5 encodes a protein with SH2 and SH3 domains. Nature (1992) 5.59
Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Natl Acad Sci U S A (1989) 5.10
Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature (1993) 4.61
Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem (1998) 3.97
A Drosophila SH2-SH3 adaptor protein implicated in coupling the sevenless tyrosine kinase to an activator of Ras guanine nucleotide exchange, Sos. Cell (1993) 3.94
Expression cDNA cloning of the KGF receptor by creation of a transforming autocrine loop. Science (1991) 3.69
An SH3-SH2-SH3 protein is required for p21Ras1 activation and binds to sevenless and Sos proteins in vitro. Cell (1993) 3.40
Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett (1976) 3.35
A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1. Mol Cell Biol (1991) 3.13
The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science (1993) 3.12
Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol Cell Biol (1996) 2.80
Soluble dominant-negative receptor uncovers essential roles for fibroblast growth factors in multi-organ induction and patterning. EMBO J (1998) 2.07
Characterization of the receptor for keratinocyte growth factor. Evidence for multiple fibroblast growth factor receptors. J Biol Chem (1990) 1.62
FGF-7 (keratinocyte growth factor) expression during mouse development suggests roles in myogenesis, forebrain regionalisation and epithelial-mesenchymal interactions. Mech Dev (1994) 1.53
Inducible expression of keratinocyte growth factor (KGF) in mice inhibits lung epithelial cell death induced by hyperoxia. Proc Natl Acad Sci U S A (2003) 1.41
Keratinocyte growth factor is a growth factor for mammary epithelium in vivo. The mammary epithelium of lactating rats is resistant to the proliferative action of keratinocyte growth factor. Am J Pathol (1994) 1.21
Overexpression of the Grb2 gene in human breast cancer cell lines. Oncogene (1994) 1.12
Ras superfamily monomeric G proteins in carcinoma cell motility. Cancer Lett (2003) 1.08
Grb2 overexpression in nuclei and cytoplasm of human breast cells: a histochemical and biochemical study of normal and neoplastic mammary tissue specimens. J Pathol (1997) 1.07
HGF- and KGF-induced activation of PI-3K/p70 s6 kinase pathway in corneal epithelial cells: its relevance in wound healing. Exp Eye Res (2001) 1.05
Shc and a novel 89-kDa component couple to the Grb2-Sos complex in fibroblast growth factor-2-stimulated cells. J Biol Chem (1995) 1.02
Keratinocyte growth factor. A fibroblast growth factor family member with unusual target cell specificity. Ann N Y Acad Sci (1991) 1.01
Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. Oncogene (1999) 1.01
Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. Am J Physiol (1998) 1.01
Keratinocyte growth factor-induced motility of breast cancer cells. Clin Exp Metastasis (2000) 1.00
Keratinocyte growth factor induces angiogenesis and protects endothelial barrier function. J Cell Sci (1999) 0.99
Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice. Oncogene (1996) 0.95
Activation of mitogen-activated protein kinase pathway by keratinocyte growth factor or fibroblast growth factor-10 promotes cell proliferation in human endometrial carcinoma cells. J Clin Endocrinol Metab (2003) 0.94
Keratinocyte growth factor as a cytokine that mediates mesenchymal-epithelial interaction. EXS (1995) 0.93
Influence of antiestrogens on the migration of breast cancer cells using an in vitro wound model. Clin Exp Metastasis (1997) 0.88
Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells. Oncogene (2000) 0.87
Expression of keratinocyte growth factor and its receptor in human breast cancer. Br J Cancer (1997) 0.85
Detection of aromatase and keratinocyte growth factor expression in breast tumors using reverse transcription-polymerase chain reaction. J Steroid Biochem Mol Biol (1993) 0.85
The role of mitogen-activated protein kinase activation within focal adhesions in chemotaxis toward FGF-2 by murine brain capillary endothelial cells. Exp Cell Res (2001) 0.83
Src/ERK but not phospholipase D is involved in keratinocyte growth factor-stimulated secretion of matrix metalloprotease-9 and urokinase-type plasminogen activator in SNU-16 human stomach cancer cell. J Cancer Res Clin Oncol (2002) 0.80
Antisense KGFR oligonucleotide inhibition of KGF-induced motility in breast cancer cells. Anticancer Res (2004) 0.80
A new function for phospholipase C-gamma1: coupling to the adaptor protein GRB2. Arch Biochem Biophys (1997) 0.76
Preparation and application of liposome-incorporated oligodeoxynucleotides. Methods Enzymol (2000) 0.75
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res (2007) 1.90
Src activation regulates anoikis in human colon tumor cell lines. Oncogene (2002) 1.70
The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem (2003) 1.56
Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol (2009) 1.37
Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem (2003) 1.34
Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther (2007) 1.29
Telomere 3' overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells. FASEB J (2007) 1.22
Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer. Proteomics (2008) 1.15
Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clin Cancer Res (2012) 1.12
TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells. Breast Cancer Res (2008) 1.11
Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J Thorac Oncol (2010) 1.08
HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells. Oncogene (2005) 1.07
Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma. Clin Cancer Res (2007) 1.06
Programmed cell death 4 inhibits breast cancer cell invasion by increasing tissue inhibitor of metalloproteinases-2 expression. Breast Cancer Res Treat (2008) 0.99
all-trans-Retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia. Am J Hematol (2002) 0.96
JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells. Int J Oncol (2011) 0.96
Leptin utilizes Jun N-terminal kinases to stimulate the invasion of MCF-7 breast cancer cells. Clin Exp Metastasis (2008) 0.92
The potential of drug-carrying immunoliposomes as anticancer agents. Commentary re: J. W. Park et al., Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery. Clin. Cancer Res., 8: 1172-1181, 2002. Clin Cancer Res (2002) 0.91
Downregulation of Wilms' tumor 1 protein inhibits breast cancer proliferation. Biochem Biophys Res Commun (2002) 0.91
Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity. Cancer Res (2009) 0.90
Cyclooxygenase-2 uses the protein kinase C/ interleukin-8/urokinase-type plasminogen activator pathway to increase the invasiveness of breast cancer cells. Int J Oncol (2007) 0.89
Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells. Cancer Res (2004) 0.89
Expression of prohibitin 3' untranslated region suppressor RNA alters morphology and inhibits motility of breast cancer cells. J Mol Histol (2004) 0.89
N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells. Carcinogenesis (2005) 0.85
A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide. Mol Cancer Ther (2002) 0.85
Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia. PLoS One (2013) 0.85
N-(4-Hydroxyphenyl)retinamide and nitric oxide pro-drugs exhibit apoptotic and anti-invasive effects against bone metastatic breast cancer cells. Carcinogenesis (2005) 0.84
Influence of KGF on the progression of pancreatic cancer. Anticancer Res (2009) 0.84
Targeting a methioninase-containing fusion protein to breast cancer urokinase receptors inhibits growth and migration. Anticancer Res (2006) 0.83
The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo. J Pharmacol Exp Ther (2004) 0.83
Influence of novel KGFR tyrosine kinase inhibitors on KGF-mediated proliferation of breast cancer. Anticancer Res (2010) 0.81
Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer. Mol Cancer Ther (2010) 0.81
Cellular pharmacology of P-ethoxy antisense oligonucleotides targeted to Bcl-2 in a follicular lymphoma cell line. Leuk Lymphoma (2003) 0.81
Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency. Biochem Pharmacol (2005) 0.81
Bcl-2-related antisense therapy. Semin Oncol (2002) 0.80
Keratinocyte growth factor stimulates the migration and proliferation of breast cancer cells in a culture wounding model. Pharmacol Res (2002) 0.80
Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulates. J Pharmacol Exp Ther (2002) 0.80
Antisense KGFR oligonucleotide inhibition of KGF-induced motility in breast cancer cells. Anticancer Res (2004) 0.80
Nuclear retinoid receptors are involved in N-(4-hydroxyphenyl) retinamide (Fenretinide)-induced gene expression and growth inhibition in HL-60 acute myeloid leukemia cells. Leuk Lymphoma (2004) 0.80
SiRNA inhibition of ER-alpha expression reduces KGF-induced proliferation of breast cancer cells. Anticancer Res (2008) 0.79
Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells. Breast Cancer Res (2007) 0.79
Multiple mechanisms of action of ZR2002 in human breast cancer cells: a novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNA. Int J Cancer (2004) 0.79
Enhanced motility of KGF-transfected breast cancer cells. Anticancer Res (2006) 0.78
The effect of antiestrogens on TGF-beta-mediated chemotaxis of human breast cancer cells. Anticancer Res (2002) 0.78
Specific and non-specific KGF inhibition of KGF-induced breast cancer cell motility. Anticancer Res (2003) 0.78
The HER2/Grb2/Akt pathway regulates the DNA binding activity of AP-1 in breast cancer cells. Oncol Rep (2004) 0.78
Targeting of a novel fusion protein containing methioninase to the urokinase receptor to inhibit breast cancer cell migration and proliferation. Cancer Chemother Pharmacol (2003) 0.77
Programmed cell death 4 inhibits leptin-induced breast cancer cell invasion. Oncol Rep (2011) 0.77
Liposomal antisense oligonucleotides for cancer therapy. Methods Enzymol (2004) 0.77
N-(4-hydroxyphenyl)-retinamide selectively increases All-TRANS retinoic acid inhibitory effects in HER2/NEU-overexpressing breast cancer cells. Tumour Biol (2003) 0.77
Cyclooxygenase-2 utilizes Jun N-terminal kinases to induce invasion, but not tamoxifen resistance, in MCF-7 breast cancer cells. Oncol Rep (2013) 0.76
HER2/neu uses Akt to suppress retinoic acid response element binding activity in MDA-MB-453 breast cancer cells. Int J Oncol (2003) 0.76
Development of keratinocyte growth factor receptor tyrosine kinase inhibitors for the treatment of cancer. Anticancer Res (2008) 0.76
Selective growth inhibition of cancer cells by L-methioninase-containing fusion protein targeted to the urokinase receptor. Pharmacology (2009) 0.75
Wilms' tumor 1 protein and focal adhesion kinase mediate keratinocyte growth factor signaling in breast cancer cells. Anticancer Res (2008) 0.75
Effect of antiestrogens on EGF-mediated movement of human breast cancer cells. Pharmacology (2006) 0.75
Cyclosporin A enhances the apoptotic effects of N-(4-hydroxyphenyl)retinamide in breast cancer cells. Int J Cancer (2002) 0.75
Influence of L-methioninase targeted to the urokinase receptor on the proliferation and motility of lung and prostate cancer cells. Anticancer Res (2007) 0.75